Back to Clinical Trials
N/ARecruiting

MYLUNG Consortium Part 3: Observational Study

Sponsored by US Oncology Research

About this study

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Lung cancer remains the most lethal malignancy in men and women in the U.S. Providing high quality management of these patients in the community setting as compared to hospital or academic centers offers the opportunity to reduce cost without sacrificing clinical outcome and simultaneously improving patient convenience and value. Many patients diagnosed with late-stage cancers can benefit from advanced biomarker testing, yet not all eligible patients receive this type of diagnostic testing today. Within advanced non-small-cell lung cancer (aNSCLC), there are many specific somatic mutations observed in select patient populations that have targeted highly effective and less toxic therapies. National guidelines have advocated for broad tumor molecular profiling as a part of the standard diag…

Where this study is enrolling (10)

Show all 10 locations

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio

    I'm interested

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

    I'm interested

  • Virginia Oncology Associates

    Newport News, Virginia

    I'm interested

  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Blacksburg, Virginia

    I'm interested

  • Northwest Cancer Specialists, P.C.

    Vancouver, Washington

    I'm interested
Who can participate

Inclusion criteria

  • ✓Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer
  • ✓Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment.
  • ✓Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease
  • ✓Subjects must be enrolled within 30 days of initiation of systemic therapy
  • ✓Signed informed consent

Exclusion criteria

  • ✕Stage IA at the time of enrollment
  • ✕Subjects with small cell lung cancer
  • ✕Subjects with Unknown primary tumor origin

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.